Key Points
- SOPHiA GENETICS CTO Abhimanyu Verma sold 5,000 shares at an average price of $7.60, generating $38,000 under a pre-arranged Rule 10b5-1 plan. He retains 182,171 shares, with the sale reducing his ownership by 2.67%.
- The company’s latest quarter included an adjusted loss of $0.26 per share, missing estimates, although revenue of $23.31 million exceeded expectations. Analysts expect a full-year loss of $0.77 per share.
- Analyst sentiment is mixed but the consensus rating is Hold, with a $10.00 target price; the stock recently traded near its 52-week high at $7.67, while institutional investors own 31.59% of shares.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.60, for a total transaction of $38,000.00. Following the completion of the sale, the chief technology officer owned 182,171 shares in the company, valued at approximately $1,384,499.60. This trade represents a 2.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Abhimanyu Verma also recently made the following trade(s):
- On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total transaction of $34,750.00.
- On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total value of $26,953.50.
- On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.51, for a total value of $38,261.44.
SOPHiA GENETICS Trading Down 0.5%
Shares of NASDAQ SOPH opened at $7.67 on Tuesday. SOPHiA GENETICS SA has a 1-year low of $2.96 and a 1-year high of $7.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The business's 50 day moving average is $5.68 and its two-hundred day moving average is $5.16. The stock has a market capitalization of $643.44 million, a P/E ratio of -6.67 and a beta of 0.96.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, research analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have commented on SOPH. BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus target price of $10.00.
Check Out Our Latest Research Report on SOPH
Hedge Funds Weigh In On SOPHiA GENETICS
Institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the fourth quarter worth $49,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
